This intricate regulatory axis potently influences the cellular adaptive and pathophysiological responses in COPD, suggesting SNHG4 and miR-409-3p as potential therapeutic targets for ameliorating disease progression. This evidence concerns the gene SNHG4 and chronic obstructive pulmonary disease.